- In November 2024, Astellas opened two advanced innovation centers in the U.S.—the West Coast Innovation Center in South San Francisco and the Life Sciences Center in Cambridge. These facilities aim to foster collaboration, scientific progress, and new treatments for Europe patients
- In October 2024, Viatris announced an exclusive licensing agreement with Lexicon Pharmaceuticals for sotagliflozin in all markets outside the U.S. and Europe. Approved by the FDA in 2023, the agreement expanded Viatris' cardiovascular portfolio, leveraging its Europe infrastructure to address unmet medical needs
- In January 2023, Viatris completed its acquisition of Oyster Point Pharma and Famy Life Sciences, forming the new Viatris Eye Care Division. Jeffrey Nau, former CEO of Oyster Point Pharma, led the division, aiming to expand their portfolio and create a Europe eye care leader
- In October 2024, AbbVie has reached an agreement to acquire Aliada Therapeutics .The acquisition includes Aliada's novel blood-brain barrier technology and its lead candidate, ALIA-1758, an anti-amyloid antibody for Alzheimer's treatment
- In April 2024, AbbVie has completed its acquisition of Cerevel Therapeutics, enhancing its neuroscience portfolio. The acquisition includes Cerevel’s promising clinical-stage assets like Emraclidine for schizophrenia and Tavapadon for Parkinson's disease, strengthening AbbVie’s position in neurology and psychiatry
